Exelixis (NASDAQ:EXEL) has witnessed a rise of 2.1% or 994,285 shares in its short figure. The short interest augmentation took it from 46,936,466 on May 31,2016 to 47,930,751 on June 15,2016. In terms of floated shares, the short interest was calculated to be 23%. The days to cover are 7 given that the daily volume averaged 6,439,739 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Exelixis (NASDAQ:EXEL): The stock opened at $7.33 on Friday but the bulls could not build on the opening and the stock topped out at $7.86 for the day. The stock traded down to $7.20 during the day, due to lack of any buying support eventually closed down at $7.69 with a loss of -2.04% for the day. The stock had closed at $7.85 on the previous day. The total traded volume was 11,569,801 shares.
The company shares have rallied 117.23% from its 1 Year high price. On Jun 23, 2016, the shares registered one year high at $7.88 and the one year low was seen on Jul 6, 2015. The 50-Day Moving Average price is $6.49 and the 200 Day Moving Average price is recorded at $4.96.
Exelixis (NASDAQ:EXEL) has climbed 1.18% in the past week and advanced 21.29% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 2.86% and the outperformance has advanced to 24.96% for the last 4 weeks period.
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Companys other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).